Eterogeneità tumorale intra-paziente ed efficacia di sacituzumab govitecan

Advanced triple negative breast cancer (TNBC) represents a challenging clinical condition with limited therapeutics opportunities. However, recently, a new antibody drug conjugated, sacituzumab govitecan, demonstrated a relevant clinical efficacy in this setting of patients. In this report we describe the case of a patient with TNBC diagnosed at the metastatic level when the primary breast tumour presented overexpression of ER end PgR. An important tumoral heterogeneity has been described in breast cancer during its natural evolution and for that reason is important to perform metastatic lesions re-biopsy, when feasible, in order to re-evaluate the biological characteristics and define the optimal therapeutic strategy.